Sam F. B. van Beuningen

Sam F. B. van Beuningen

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 March 2024 in Communications Biology
Verified
Journal Article
Open access
PDF file
JLJuliet W. Lefferts
Juliet W. Lefferts
SKSuzanne Kroes
Suzanne Kroes
MSMatthew B. Smith
Matthew B. Smith
PNPaul J. Niemöller
Paul J. Niemöller
NNNatascha D. A. Nieuwenhuijze
Natascha D. A. Nieuwenhuijze
SBSam F. B. van Beuningen
Sam F. B. van Beuningen
Epithelial ion and fluid transport studies in patient-derived organoids (PDOs) are increasingly being used for preclinical studies, drug development and precision medicine applications. Epithelial fluid transport properties in PDOs can be measured through visual changes in organoid (lumen) size. Such organoid phenotypes have been highly instrumental for the studying of diseases, including cystic fibrosis (CF), which is characterized by genetic mutations of the CF transmembrane conductance regulator (CFTR) ion channel. Here we present OrgaSegment, a MASK-RCNN based deep-learning segmentation model allowing for the segmentation of individual intestinal PDO structures from bright-field images. OrgaSegment recognizes spherical structures in addition to the oddly-shaped organoids that are a hallmark of CF organoids and can be used in organoid swelling assays, including the new drug-induced swelling assay that we show here. OrgaSegment enabled easy quantification of organoid swelling and could discriminate between organoids with different CFTR mutations, as well as measure responses to CFTR modulating drugs. The easy-to-apply label-free segmentation tool can help to study CFTR-based fluid secretion and possibly other epithelial ion transport mechanisms in organoids.

Verified
Journal Article
Open access
PDF file
JLJuliet W. Lefferts
Juliet W. Lefferts
MBMarlou Corine Bierlaagh
Marlou Corine Bierlaagh
SKSuzanne Kroes
Suzanne Kroes
NNNatascha D. A. Nieuwenhuijze
Natascha D. A. Nieuwenhuijze
HKHeleen N. Sonneveld van Kooten
Heleen N. Sonneveld van Kooten
JBJeffrey M. Beekman
Jeffrey M. Beekman
Cystic fibrosis (CF) is caused by mutations in the Cystic Fibrosis Transmembrane conductance Regulator (CFTR) gene. The combination of the CFTR modulators elexacaftor, tezacaftor, and ivacaftor (ETI) enables the effective rescue of CFTR function in people with the most prevalent F508del mutation. However, the functional restoration of rare CFTR variants remains unclear. Here, we use patient-derived intestinal organoids (PDIOs) to identify rare CFTR variants and potentially individuals with CF that might benefit from ETI. First, steady-state lumen area (SLA) measurements were taken to assess CFTR function and compare it to the level observed in healthy controls. Secondly, the forskolin-induced swelling (FIS) assay was performed to measure CFTR rescue within a lower function range, and to further compare it to ETI-mediated CFTR rescue in CFTR genotypes that have received market approval. ETI responses in 30 PDIOs harboring the F508del mutation served as reference for ETI responses of 22 PDIOs with genotypes that are not currently eligible for CFTR modulator treatment, following European Medicine Agency (EMA) and/or U.S. Food and Drug Administration (FDA) regulations. Our data expand previous datasets showing a correlation between in vitro CFTR rescue in organoids and corresponding in vivo ppFEV1 improvement upon a CFTR modulator treatment in published clinical trials, and suggests that the majority of individuals with rare CFTR variants could benefit from ETI. CFTR restoration was further confirmed on protein levels using Western blot. Our data support that CFTR function measurements in PDIOs with rare CFTR genotypes can help to select potential responders to ETI, and suggest that regulatory authorities need to consider providing access to treatment based on the principle of equality for people with CF who do not have access to treatment.

Verified
Journal Article
Open access
PDF file
LRLisa Rodenburg
Lisa Rodenburg
LDLivia Delpiano
Livia Delpiano
VRVioleta Railean
Violeta Railean
RCRaquel Centeio
Raquel Centeio
MPMadalena Pinto
Madalena Pinto
GAGimano D. Amatngalim
Gimano D. Amatngalim
Individuals with cystic fibrosis (CF) suffer from severe respiratory disease due to a genetic defect in the cystic fibrosis transmembrane conductance regulator (CFTR) gene, which impairs airway epithelial ion and fluid secretion. New CFTR modulators that restore mutant CFTR function have been recently approved for a large group of people with CF (pwCF), but ~19% of pwCF cannot benefit from CFTR modulators Restoration of epithelial fluid secretion through non-CFTR pathways might be an effective treatment for all pwCF. Here, we developed a medium-throughput 384-well screening assay using nasal CF airway epithelial organoids, with the aim to repurpose FDA-approved drugs as modulators of non-CFTR-dependent epithelial fluid secretion. From a ~1400 FDA-approved drug library, we identified and validated 12 FDA-approved drugs that induced CFTR-independent fluid secretion. Among the hits were several cAMP-mediating drugs, including β2-adrenergic agonists. The hits displayed no effects on chloride conductance measured in the Ussing chamber, and fluid secretion was not affected by TMEM16A, as demonstrated by knockout (KO) experiments in primary nasal epithelial cells. Altogether, our results demonstrate the use of primary nasal airway cells for medium-scale drug screening, target validation with a highly efficient protocol for generating CRISPR-Cas9 KO cells and identification of compounds which induce fluid secretion in a CFTR- and TMEM16A-indepent manner.

29 July 2026 in bioRxiv
Verified
Preprint
Open access
PDF file
BBBram M. Bosch
Bram M. Bosch
MTMaarten Terpstra
Maarten Terpstra
MSMatthew B. Smith
Matthew B. Smith
KSKrijn H. van der Steen
Krijn H. van der Steen
CJCaspar T.H. Jonker
Caspar T.H. Jonker
SBSam F. B. van Beuningen
Sam F. B. van Beuningen
Microscopy-based phenotypic profiling relies increasingly on autonomous, unsupervised feature extraction, yet no existing method explicitly separates shape from texture into dedicated and independent latent subspaces by architectural design. Therefore texture, encoding critical biological information such as protein distribution and intracellular organisation, remains inaccessible as an independent feature domain in standard unsupervised approaches. This represents a fundamental limitation that prevents unbiased phenotypic analysis across biological scales. Here we introduce UDIST (Unsupervised Disentanglement of Shape and Texture), a sequential dual variational autoencoder (VAE) framework that tackles this fundamental limitation by explicitly decoupling shape from texture into independent, non-overlapping latent subspaces at the single-object level. By training two VICReg-regularised VAEs on principal-axis-aligned objects, UDIST separates binary shape from continuous texture information into rotation-invariant feature spaces, enabling separate downstream analysis of both domains. We validated UDIST across biological scales, from nuclei and single cells to patient-derived intestinal organoids, using both fluorescence and brightfield imaging, revealing phenotypic differences previously hidden by morphological variation and enabling the independent analysis of shape and texture in downstream analyses including clustering and similarity measurements. UDIST provides a versatile, label-free, and unsupervised tool for multi-scale phenotypic profiling in high-content microscopy and screening.

27 August 2026 in bioRxiv
Verified
Preprint
Open access
PDF file
NNNguyen T.B. Nguyen
Nguyen T.B. Nguyen
RKRutger N.U. Kok
Rutger N.U. Kok
SGSira Gevers
Sira Gevers
XZXuan Zheng
Xuan Zheng
MBMax A. Betjes
Max A. Betjes
MCMaria J. Rodriguez Colman
Maria J. Rodriguez Colman
Organoid models have transformed our understanding of intestinal renewal. Fluorescent imaging has been extensively used to identify key cell types and their differentiation pathways, but immunofluorescence provides only static readouts, whereas live imaging requires fluorescent-reporter engineering and is constrained by limited multiplexing and spectral overlap. Here, we introduce NuclearIDTracker, an explainable machine-learning framework that infers cell identity directly from 3D nuclear segmentations. Using a single nuclear marker, NuclearIDTracker accurately classifies intestinal cell types and integrates with single-cell tracking to resolve lineages and reconstruct dynamic state transitions during organoid development. We show that TA-like cells, rather than stem cells, drive early crypt formation and generate enterocyte and Paneth lineages, as well as the stem-cell population, which emerges only later and subsequently replenishes the TA-like compartment. Following stem-cell ablation, crypt regeneration was not driven by a single discrete cell type. Instead, multiple epithelial populations converged on a proliferative regenerative state with a nuclear phenotypic signature that resembled, but remained distinct from, that of homeostatic TA-like cells, and a YAP/TAZ-associated fetal-like transcriptional signature. Thus, nuclear phenotypic signatures resolve cell identity and reveal coordinated epithelial plasticity during crypt regeneration. NuclearIDTracker establishes a non-perturbative tool to quantify cell identity and state dynamics at single-cell resolution, revealing previously inaccessible biological dynamics and expanding the toolkit for studying epithelial homeostasis, regeneration, and disease.